Clinical Trial Update: ENCOrafenib With Binimetinib in bRAF NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating encorafenib plus binimetinib in non-small cell lung cancer with BRAF V600E mutation; current status is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Binimetinib (Mektovi) (binimetinib)
• Encorafenib (Braftovi) (encorafenib)

Snippet

Sponsor: Intergroupe Francophone de Cancerologie Thoracique | Conditions: Non Small Cell Lung Cancer, BRAF V600E | Phase 2 | Status: ACTIVE_NOT_RECRUITING